Evidence map›Paper›PMID 17825262›Full record

ReviewBiochemical pharmacology2007

The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Sharon R Grady, Outi Salminen, Duncan C Laverty, Paul Whiteaker, J Michael McIntosh, Allan C Collins, Michael J Marks

Abstract readReview
In one paragraph

Review in Biochemical pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 4 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 4 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Role of microRNAs in the pathophysiology of addiction.Wiley interdisciplinary reviews. RNA · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. "Unraveling the role ofReceptors (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. The many enigmas of nicotine.Advances in pharmacology (San Diego, Calif.) · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sharon R GradyInstitute for Behavioral Genetics, University of Colorado, Boulder, CO 80309, USA. sharon.grady@colorado.edu
Outi Salminen
Duncan C Laverty
Paul Whiteaker
J Michael McIntosh
Allan C Collins
Michael J Marks
University of Colorado Boulder · USUniversity of Helsinki · FIUniversity of Utah · US

Funding

Project 3 University of Colorado, BoulderU19DA019375 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI LESTER, HENRY A. · 2005 to 2014
$8.3M
GENETICS OF NICOTINE TOLERANCE: ROLE OF RECEPTORSR01DA003194 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI MARKS, MICHAEL J · 1985 to 2013
$5.5M
Studies with Nicotinic Null Mutant MiceP30DA015663 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI MARKS, MICHAEL J · 2003 to 2013
$4.5M
Alpha4 Nicotinic Receptor in Addiction: Mouse ModelsR01DA017279 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI LESTER, HENRY A. · 2004 to 2014
$3.5M
ALPHA-CONOTOXIN MII--SELECTIVE NICOTINIC RECEPTOR PROBER01DA012242 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI WHITEAKER, PAUL · 1999 to 2011
$3.5M
NIDA NIH HHS DA015663NIDA NIH HHS DA019375NIDA NIH HHS DA03194NIDA NIH HHS DA12242NIDA NIH HHS P30 DA015663NIDA NIH HHS R01 DA003194NIDA NIH HHS R01 DA012242NIDA NIH HHS R01 DA017279NIDA NIH HHS U19 DA019375
6 · The paper itself

Abstract

This review summarizes studies that attempted to determine the subtypes of nicotinic acetylcholine receptors (nAChR) expressed in the dopaminergic nerve terminals in the mouse. A variety of experimental approaches has been necessary to reach current knowledge of these subtypes, including in situ hybridization, agonist and antagonist binding, function measured by neurotransmitter release from synaptosomal preparations, and immunoprecipitation by selective antibodies. Early developments that facilitated this effort include the radioactive labeling of selective binding agents, such as [(125)I]-alpha-bungarotoxin and [(3)H]-nicotine, advances in cloning the subunits, and expression and evaluation of function of combinations of subunits in Xenopus oocytes. The discovery of epibatidine and alpha-conotoxin MII (alpha-CtxMII), and the development of nAChR subunit null mutant mice have been invaluable in determining which nAChR subunits are important for expression and function in mice, as well as allowing validation of the specificity of subunit specific antibodies. These approaches have identified five nAChR subtypes of nAChR that are expressed on dopaminergic nerve terminals. Three of these contain the alpha6 subunit (alpha4alpha6beta2beta3, alpha6beta2beta3, alpha6beta2) and bind alpha-CtxMII with high affinity. One of these three subtypes (alpha4alpha6beta2beta3) also has the highest sensitivity to nicotine of any native nAChR that has been studied, to date. The two subtypes that do not have high affinity for alpha-CtxMII (alpha4beta2, alpha4alpha5beta2) are somewhat more numerous than the alpha6* subtypes, but do bind nicotine with high affinity. Given that our first studies detected readily measured differences in sensitivity to agonists and antagonists among these five nAChR subtypes, it seems likely that subtype selective compounds could be developed that would allow therapeutic manipulation of diverse nAChRs that have been implicated in a number of human conditions.

Indexed as

AnimalsBridged Bicyclo Compounds, HeterocyclicBungarotoxinsConotoxinsCorpus StriatumDopamineMicePyridinesReceptors, Nicotinicalpha-conotoxin MIIBridged Bicyclo Compounds, HeterocyclicBungarotoxinsConotoxinsDopamineepibatidinePyridinesReceptors, Nicotinic

Identifiers

PMID17825262
PMCPMC2735219
OpenAlexW1970133822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.